A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in diagnoses at later stages of the disease. By Rebecca Robbins and Gina Kolata A ...

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...

In real-world clinical practice, adding p‑tau217 testing significantly improved diagnostic accuracy and increased neurologists' diagnostic confidence, with marked reclassification seen in mild ...

Feb 20 (Reuters) - Grail's (GRAL.O), opens new tab shares plunged nearly 50% on Friday after the company said routine screening with its cancer blood test failed to significantly boost early detection ...

A large, three-year clinical trial designed to demonstrate how Grail’s blood test for early cancer detection could work in a broad population has preliminary results showing reduction in late-stage ...

Blood tests that detect a protein involved in Alzheimer’s disease could help predict the age at which the disease may strike people long before they develop symptoms, according to a new study. But ...

As AI systems began acing traditional tests, researchers realized those benchmarks were no longer tough enough. In response, nearly 1,000 experts created Humanity’s Last Exam, a massive 2,500-question ...

Scientists have created a blood test that can estimate when Alzheimer’s symptoms are likely to begin. By measuring a protein called p-tau217, the model predicts symptom onset within roughly three to ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Having a slower TUG time and standing on one leg for ...

Tests that once challenged advanced AI models are now being solved with ease, making it harder for researchers to pinpoint what current systems are actually capable of.